Aflac Incorporated

(New York Stock Exchange)
Back to all articles
Slightly Bullish +25

Aflac stock: Mizuho raises target but keeps Underperform rating

Earnings report Price target change AI-generated analysis

πŸ“‰ Mizuho raised Aflac's price target to $112 but maintained an Underperform rating following a mixed third-quarter report.

πŸ’° Normalized Q3 earnings per share hit $1.80, matching consensus, while adjusted EPS reached $2.43 due to actuarial assumption changes.

πŸ“‰ Revenue of $3.27 billion missed the $4.11 billion consensus estimate cited by analysts.

πŸ“ˆ Mizuho lifted its fiscal 2026 EPS forecast by 9% to $7.70, with similar increases for fiscal 2027 and 2028.

πŸ‡―πŸ‡΅ New premium equivalents are shrinking in Japan, creating headwinds for growth in that key market.

πŸ‡ΊπŸ‡Έ US new premium equivalents growth remains in the lower half of Aflac's internal target range.

πŸ’Έ A planned cession of 500 billion yen in cancer reserves is expected to release approximately $1 billion in capital.

πŸ“Š Portfolio switch trades have added over $80 million in annualized net investment income year-to-date.

βš–οΈ Future earnings growth depends on the strategic deployment of released capital and improved benefit ratios.

🏦 Aflac stock traded at 112.00 euros on the New York Stock Exchange as of Tuesday, November 10, 2026.

Bullish Signals
  • Mizuho raised its price target for Aflac from $107 to $112 following a third-quarter headline earnings beat.
  • Mizuho increased its fiscal 2026 EPS estimate by 9% to $7.70, reflecting a narrower US discount to the wider group.
  • A planned cession of 500 billion yen in cancer reserves is expected to release roughly $1 billion of capital for deployment.
  • Portfolio switch trades have generated more than $80 million in annualized net investment income so far this year.
  • Actuarial assumption changes boosted adjusted earnings per share to $2.43, contrasting with weaker revenue.
Risk Factors
  • Revenue of $3.27 billion fell significantly below the $4.11 billion consensus expectation for the third quarter.
  • New premium equivalents continue to shrink in Japan, indicating weakening demand in a key market.
  • US new premium equivalents growth remains in the lower half of management's target range, signaling softness.
  • Mizuho maintains an Underperform rating despite raising the price target, citing mixed operating trends.
  • Future earnings growth is contingent on capital deployment rather than organic top-line expansion.
Full Analysis
Aflac Inc. received a mixed analyst reaction following its third-quarter report, with Mizuho raising its price target to $112 while maintaining an Underperform rating. The insurer reported normalized earnings per share of $1.80, which matched consensus estimates, though adjusted earnings reached $2.43 due to actuarial assumption changes. Revenue for the quarter came in at $3.27 billion, falling short of the $4.11 billion consensus expectation. Mizuho increased its fiscal 2026 earnings-per-share forecast by 9% to $7.70, with subsequent years also seeing slight upward revisions. These adjustments reflect a headline earnings beat and a narrower US discount relative to the wider group. However, the underlying operating picture remains uneven, characterized by shrinking new premium equivalents in Japan and US growth that sits in the lower half of management's target range. The company is executing strategic capital moves, including a planned cession of approximately 500 billion yen in cancer reserves to Aflac Re Bermuda, expected to release roughly $1 billion in capital. Additionally, portfolio switch trades have generated over $80 million in annualized net investment income year-to-date. While these actions enhance capital flexibility and potential for shareholder returns, Mizuho notes that future earnings growth remains contingent on how this capital is deployed.